Surgical cryoablation for ventricular tachyarrhythmia in patients undergoing surgical ventricular restoration: Lessons learned from radiofrequency ablation  by Parachuri, Rao V. & Adhyapak, Srilakshmi M.
Surgical Techniques3. Navia JL, Atik FA,Marullo A, Starling RC, Garcia M, Vega PR, et al. Bench repair
of donor aortic valve with minimal access orthotopic heart transplantation. Ann
Thorac Surg. 2005;80:313-5.
4. Boodhwani M, de Kerchove L, Glineur D, Rubay J, Vanoverschelde JL, Van
Dyck M, et al. Aortic valve repair with ascending aortic aneurysms: associated le-From the Division of Cardiovascular Surgery, University of Pennsylvania, Philadel-
phia, Pa.
Disclosures: Authors have nothing to disclose with regard to commercial support.
Received for publication Jan 10, 2012; revisions received Jan 30, 2012; accepted for
publication March 12, 2012; available ahead of print April 9, 2012.
Address for reprints: Srilakshmi M. Adhyapak, DNB, c/o V. Rao Parachuri,
FRCS(Cth), Narayana Hrudayalaya Institute of Medical Sciences; 258/A, Bomma-
sandra Industrial Area, Anekal Taluk, Bangalore 560099, India (E-mail:
srili2881967@yahoo.com).
J Thorac Cardiovasc Surg 2012;144:724-6
0022-5223/$36.00
Copyright  2012 by The American Association for Thoracic Surgery
http://dx.doi.org/10.1016/j.jtcvs.2012.03.023
724 The Journal of Thoracic and Cardiovascular Surgsions and adjunctive techniques. Eur J Cardiothorac Surg. 2011;40:424-8. Epub
2011 Jan 13.
5. DavidTE, Feindel CM,Armstrong S,MagantiM.Replacement of the ascendingaorta
with reductionof the diameter of the sinotubular junction to treat aortic insufficiency in
patients with ascending aortic aneurysm. J Thorac Cardiovasc Surg. 2007;133:414-8.Surgical cryoablation for ventricular tachyarrhythmia in patients
undergoing surgical ventricular restoration: Lessons learned from














FIGURE 1. Linear endoventricular patch used to exclude the infarcted
myocardium. (Reprinted with permission from Parachuri VR, Adhyapak
SM, Kumar P, Setty R, Rathod R, Shetty DP. Ventricular restoration by lin-
ear endoventricular patchplasty and linear repair. Asian Cardiovasc Thorac
Ann. 2008;16:401-6.)With the limited number of available donor hearts, ther-
apeutic options are limited even for those patients who
are eligible for transplantation. The clinical presentation
of patients with post–myocardial infarction left ventric-
ular aneurysms is usually heart failure, angina, or ven-
tricular tachyarrhythmia. In patients with ventricular
tachyarrhythmia, the role of adjuvant arrhythmia surgery
during surgical ventricular restoration is unquestionable.
In patients who do not present with arrhythmia, how-
ever, the role of preoperative electrophysiologic testing
to demonstrate inducibility of such arrhythmia is not
clear.
The concomitant surgical procedures for arrhythmia in
the late 1970s and early 1980s included map-guided or un-
guided endocardectomy and encircling cryoablation of the
border zone. These procedures targeted ablation of ventric-
ular tachyarrhythmia caused by reentrant circuits that were
presumed to exist in the border zone.1 In the 1990s, com-
puter modeling, animal studies, and human studies demon-
strated that such circuits contain a narrow isthmus of viable
tissue and slow conduction that forms a critical part of the
ventricular tachyarrhythmia reentrant circuit and is bound
by infarcted tissue or anatomic barriers, such as the mitral
valve annulus.2,3 Radiofrequency ablation is targeted atablating this isthmus to abolish the reentrant mechanism
of ventricular tachyarrhythmia. This procedure is usually
performed after mapping the isthmus by 3-dimensional
cartography. Surgical mapping of the reentrant circuit is
cumbersome, however, and we therefore modeled our
cryoablation technique from available data on the anatomic
location of the isthmus. We now evaluate the midterm re-
sults of surgical linear cryoablation of ventricular tachyar-
rhythmia in patients undergoing surgical ventricular
restoration.CLINICAL SUMMARY
We performed linear cryoablation in 6 patients presenting
with spontaneous ventricular tachyarrhythmia who wereery c September 2012
TABLE 1. New York Heart Association functional class and echocardiographic left ventricular data
Preoperative Postoperative (30 d) 5-y Follow-up P value
Left ventricular ejection fraction 31.5%  6.5% 34.2%  5.9% 38.4%  4.5% <.001
Indexed end-diastolic volume (mL) 140.3  38.3 100.8  3.5 68.4  12.4 <.001
Indexed end-systolic volume (mL) 95.1  26.1 66  21.7 54.2  16.4 <.001
New York Heart Association functional class III/IV I/II
Values are mean  SD. P values were obtained by analysis of variance.
Surgical Techniquesscheduled for surgical ventricular restoration.4 We have not
conducted electrophysiologic testing for inducibility in pa-
tients who did not present with spontaneous ventricular
tachyarrhythmia, and none of our patients underwent preop-
erative electrophysiologic testing for inducibility. Our tech-
nique of cryoablation is modeled after the principle of
radiofrequency ablation of reentrant ventricular tachyar-
rhythmia. After opening the ventricular cavity parallel to
the left anterior descending coronary artery in anterior ven-
tricular aneurysms, we performed a linear cryoablation
starting from the posterior mitral annulus and extending
to the inferior aspect of the apical scar. We used a cryosurgi-
cal probe AA3 with a curved tip (Appasamy Associates,
Chennai, India). The probe was applied at temperatures of
60C for 2 minutes at each point. Once this cryoablation
was completed, a linear endoventricular patch was created
to exclude the infarcted myocardium (Figure 1). The in-
farcted scar was not plicated, and the patch was sized
visually.
Concomitant surgical procedures included coronary ar-
tery bypass grafting in 3 patients (with 2  1.2 grafts) and
mitral valve repair with a rigid Carpentier annuloplasty
ring (Edwards [India] Pvt. Ltd, Mumbai, India) in 2 pa-
tients with mitral regurgitation of at least grade 2. All 6
patients were subjected to postoperative electrophysio-
logic testing for arrhythmia inducibility at 6 weeks to 6
months after the surgery. None had inducible arrhythmias.
At 5-year follow-up, there were no deaths in this patient
subgroup, with significant clinical improvements as as-
sessed by New York Heart Association functional class
and significant reverse remodeling as assessed by de-
creases in left ventricular end-systolic volumes and
ejection fractions on 2-dimensional echocardiography
(Table 1).DISCUSSION
The mechanism for post–myocardial infarction ventricu-
lar tachyarrhythmia is reentry, which requires the presence
of an isthmus. An isthmus is defined as conductive myocar-
dial tissue delineated by nonconductive tissue. A depolar-
ization wave front must cross this isthmus to perpetuate
the tachyarrhythmia. As a consequence, ablation of theThe Journal of Thoracic and Cacritical isthmus interrupts the tachyarrhythmia and prevents
its reinducibility.
The localization of the critical isthmus in patients with
a history of myocardial infarction was studied by de
Chillou and coworkers.5 Four of 6 patients studied with
anterior infarctions had anterior left ventricular aneu-
rysms, and 5 of 12 patients studied with inferior infarc-
tions had inferior left ventricular aneurysms. In 86% of
patients, the reentrant circuits were anteroapical, infero-
lateral, and septal, anatomically perpendicular to the mi-
tral annular plane. One of the factors responsible for the
limited clinical success of ablation for ventricular tachy-
arrhythmia is that focal ablation may not prevent reestab-
lishment of the reentrant circuit. Radiofrequency linear
ablation is more appropriate in postinfarct ventricular
tachyarrhythmia because it can transect the critical isth-
mus. The data of de Chillou and coworkers5 demon-
strated a wide range (6–36 mm) of critical isthmus
width values, which supports the need for linear ablation
to eliminate the reentrant substrate of postinfarct ventric-
ular tachyarrhythmia. We therefore based our procedure
of linear cryoablation on these available data. A major
limitation of our study is that the beneficial effects of re-
vascularization, abolishment of mitral valve regurgita-
tion, and concomitant cryoablation on the outcomes of
heart failure and rhythm control could not be evaluated
separately.
In conclusion, with a surgical linear cryoablation lesion
similar to percutaneous radiofrequency ablation techniques,
we had no deaths, found no inducible ventricular tachyar-
rhythmia, and saw no recurrences after 5 years in patients
undergoing surgical ventricular restoration who presented
with ventricular tachyarrhythmia.References
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nafamostat mesilate in cardiac surgery: A safe option for patients
with acute strokeNaoto Morimoto, MD, PhD, Soichiro Henmi, MD, Masato Yoshida, MD, and Nobuhiko Mukohara, MD,
Himeji, JapanPatients undergoing open cardiac surgical procedures with
a history of acute stroke pose a difficult management prob-
lem. There is always the risk that cardiopulmonary bypass
(CPB) and heparinization may induce intracranial hemor-
rhage. A multicenter study suggests that open cardiac surgi-
cal procedures can be performed safely 4 weeks after
stroke1; however, some patients with acute cardiogenic
stroke occasionally require emergency surgery because of
uncontrollable heart failure or ongoing thromboembolism.
Heparinized CPB with low systemic heparinization is
among the therapeutic options when operating on patients
with the risk of intracranial hemorrhage; however, low sys-
temic heparinization could allow clot formation.2 Nafamo-
stat mesilate (6-amino-2-naphthyl p-guanidinobenzoate
dimethanesulfonate, currently available in Japan and Korea)
is a serine protease inhibitor that has such activities as anti-
coagulant effect (by inhibiting coagulation factors, XIIa, Xa,
and VIIa, along with thrombin), antifibrinolytic activities
(by inhibiting tissue-type and urokinase plasminogen acti-
vators), and antiplatelet actions.3,4 Because of a short half-
life of 8 minutes, it has recently been used mainly as an
anticoagulant for hemodialysis5 and extracorporeal mem-
brane oxygenation6 in patients with bleeding tendencies.
Nafamostat mesilate has been widely used in Japan as an al-
ternative anticoagulant agent during hemodialysis, and its
in vivo effect as an anticoagulant has been established.3
In this study, we report a successful CPB strategy
with low-dose heparin and nafamostat mesilate as ananticoagulant to reduce the dosage of heparin for patients
with acute stroke.MATERIALS AND METHODS
With approval of the institutional reviewboard and patient informed con-
sent, patients who underwent cardiac surgery with CPB with low-dose hep-
arin and nafamostat mesilate were included. From November 2007 and
January 2010, we had 17 patients with courses complicated by acute stroke.
The patient characteristics are listed in Table 1. Acute stroke was detected
by diffusion-weightedmagnetic resonance images in 16 cases, and 1 patient
had subarachnoid hemorrhage from a ruptured mycotic aneurysm. Of these
patients, 14 patients had a diagnosis of active infective endocarditis accord-
ing to modified Duke criteria. The remaining 3 patients had acute pulmo-
nary embolism with atrial septal defect, left ventricular thrombus, or left
atrial myxoma. Mean age was 63.9  16.7 years. Seven patients (41.2%)
were female. The indication for the operation was uncontrolled sepsis in
7 patients, uncontrollable heart failure in 5 patients, and ongoing thrombo-
embolism in 5 patients. Themean interval from the onset of stroke to surgery
was 2.9  0.4 days. All operations were performed as routine procedures
except for the CPB anticoagulationmanagement. Brain computed tomogra-
phy was performed within 3 days after the surgery in all cases.
Anticoagulation Protocol During CPB
Anticoagulation during CPB was managed as follows: before connec-
tion of the extracorporeal circuit, 0.8 mg/kg of nafamostat mesilate and
50 IU/kg of heparin (our normal dosage for CPB is 300 IU/kg) were admin-
istered to obtain a diatomaceous earth (Celite; World Minerals Inc, Santa
Barbara, Calif) activated clotting time (DEACT, measured with ACTII;
Medtronic BloodManagement, Parker, Colo) over 250 seconds. If DEACT
did not rise above 250 seconds, a 200-IU dose of heparin was administered.
CPB was composed of a roller pump (Mera HAS; Senko Medical
Instrument Mfg Co Ltd, Tokyo, Japan), a silicon- and heparin-coated hol-
low-fiber polypropylene oxygenator (Mera NHP Excelung Prime HPO-
23WH-C; Senko) and a heparin-coated bypass circuit (Mera Exceline-S,
0.5-inch; Senko). After connection to the pump circuit, nafamostat mesilate
and heparin were continuously infused through the venous line of the pump
circuit at 0.8/mg/(kg $ h) and 25 IU/(kg $ h), respectively. DEACT, for
which blood samples were taken from the venous circuit line every 10 min-
utes, was maintained between 400 and 600 seconds during CPB. If DEACT
exceeded 600 seconds, the continuous infusion of heparin was reduced. An
additional bolus injection of 100 IU of heparinwas administratedwhenDE-
ACT fell below 400 seconds. Furthermore, kaolin-measured ACT (KACT,
measured with Hemochron401; International Technidyne Corp, Edison,
NJ) was monitored simultaneously. KACT reflects the heparin activity inery c September 2012
